Jevtana Injection

Introduction

Jevtana is a medication that contains the active ingredient Cabazitaxel. It is available in the form of an injectable solution. This medication is commonly prescribed by healthcare professionals and is known by the brand name Jevtana.

Uses

Jevtana is primarily used in the treatment of prostate cancer. It is specifically indicated for patients with metastatic hormone-resistant prostate cancer that has progressed despite previous treatment with docetaxel-based chemotherapy. This medication works by inhibiting the growth of cancer cells and slowing down the spread of the disease.

Dosage and Administration

Jevtana is administered by a healthcare professional through a vein (intravenous infusion). The recommended dosage and infusion rate may vary depending on factors such as the patient’s body surface area and overall health condition. Follow the dosage instructions provided by your healthcare provider.

Mechanism of Action

The active ingredient in Jevtana, Cabazitaxel, belongs to a class of medications called taxanes. It works by disrupting the microtubule network in cancer cells, which are essential for cell division and growth. By interfering with this process, Cabazitaxel inhibits the growth of cancer cells and ultimately leads to their death.

Side Effects

Common side effects may include fatigue, nausea, vomiting, diarrhea, constipation, hair loss, and changes in taste. Report any persisting or bothersome side effects to your healthcare provider.

In some cases, Jevtana may cause more serious side effects. These can include low white blood cell count, which can increase the risk of infection, and low red blood cell count, which can lead to anemia. Seek immediate medical attention if you experience symptoms such as fever, chills, unusual bleeding or bruising, or shortness of breath.

Drug Interactions

Jevtana may interact with other medications. Inform your healthcare provider about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements. Some medications, such as drugs that inhibit certain liver enzymes, may affect the metabolism of Cabazitaxel and alter its effectiveness or increase the risk of side effects.

Precautions

Before using Jevtana, discuss any pre-existing medical conditions or allergies with your healthcare provider. This medication may not be suitable for everyone, and certain precautions should be taken.

Jevtana is contraindicated in patients with a known hypersensitivity to Cabazitaxel or any other ingredients in the formulation. It should also be used with caution in patients with pre-existing liver or kidney problems.

Storage

Jevtana should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). It should be kept in its original packaging to protect it from light. Do not freeze the medication, and make sure to keep it out of the reach of children.

Patient Tips

• Follow the instructions provided by your healthcare provider regarding the administration of Jevtana.
• If you miss a scheduled dose, contact your healthcare provider for further guidance.
• Report any concerning or persistent side effects to your healthcare provider.
• Maintain good hygiene and follow appropriate infection control measures to reduce the risk of infection.
• Keep all follow-up appointments with your healthcare provider to monitor your response to the medication and address any concerns.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Cabazitaxel 20 mg/ml concentrate for solution for infusion (Health Professionals SmPC) Available at:
• Cabazitaxel (Drugs.com) [Accessed 6 Jun. 2024] (online) Available at:
• cabazitaxel solution (RX) [Accessed 27 Jun. 2024] (online) Available at:
• Cabazitaxel Injection (MedlinePlus) [Accessed 21 Jun. 2024] (online) Available at:
• Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. [Accessed 28 Jun. 2024] Available at: